177472-30-9 Usage
Description
Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate) is an impurity of Levofloxacin, a synthetic broad-spectrum antibiotic belonging to the fluoroquinolone class. It is characterized by its unique chemical structure, which includes a fluorine atom, a methyl group, and a piperazinyl moiety, and is used as a reference standard for quality control and analytical testing in pharmaceutical applications.
Uses
Used in Pharmaceutical Quality Control:
Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate) is used as a reference standard for quality control in the pharmaceutical industry. It helps ensure the purity, potency, and safety of Levofloxacin, which is used to treat a wide range of bacterial infections.
Used in Analytical Testing:
Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate) is used in analytical testing to determine the presence and concentration of impurities in Levofloxacin samples. This is crucial for maintaining the quality and efficacy of the final drug product and complying with regulatory standards.
Used in Research and Development:
Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate) is also used in research and development for the study of the properties, synthesis, and potential applications of Levofloxacin and its related compounds. This can lead to the discovery of new therapeutic agents and improvements in existing treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 177472-30-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,4,7 and 2 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 177472-30:
(8*1)+(7*7)+(6*7)+(5*4)+(4*7)+(3*2)+(2*3)+(1*0)=159
159 % 10 = 9
So 177472-30-9 is a valid CAS Registry Number.
InChI:InChI=1/C20H24FN3O4/c1-4-27-20(26)14-10-24-12(2)11-28-19-16(24)13(18(14)25)9-15(21)17(19)23-7-5-22(3)6-8-23/h9-10,12H,4-8,11H2,1-3H3/t12-/m0/s1
177472-30-9Relevant articles and documents
Preparation method of levofloxacin and intermediates thereof
-
, (2021/03/30)
The invention relates to a preparation method of levofloxacin and intermediates thereof, and belongs to the field of medicinal chemistry. The preparation method comprises the following steps of: carrying out amino substitution and ring closing reaction on a fluorine-substituted substrate to integrate a plurality of intermediates into a one-pot reaction, and hydrolyzing under acidic conditions to obtain levofloxacin. According to the method, the reaction operation is simplified, the production period is greatly shortened, multiple times of after-treatment are not needed, emission of three wastes is reduced, the method is more environmentally friendly, the reaction yield is increased by about 20% compared with the prior art, and the method is suitable for industrial amplification.
Design, synthesis, and docking studies of novel ofloxacin analogues as antimicrobial agents
Jubie,Prabitha,Rajesh Kumar,Kalirajan,Gayathri,Sankar,Elango
experimental part, p. 1403 - 1410 (2012/08/07)
A number of novel ofloxacin analogues were synthesized by modifying the carboxylic acid at C-6. To investigate the antimicrobial data on structural basis, in-silico docking studies of the tested compounds into the crystal structure of topoisomerase II using Autodock vina 4.0 program was performed in order to predict the affinity and orientation of the synthesized compounds at the activities. R2 values show good agreement with predicted binding affinities obtained by molecular docking studies. Also, it is verified by in-vitro antimicrobial screening, where all the compounds were most active against Staphylococcus aureus, Staphylococcus epidermidis and Bacillus subtilis. Among these compounds 3a, 3b, 3f showed good MIC (0.125 μg/ml). Springer Science+Business Media, LLC 2011.
Spectroscopic studies on the interaction between Pr(III) complex of an ofloxacin derivative and bovine serum albumin or DNA
Xu, Min,Ma, Zhao-Rong,Huang, Liang,Chen, Feng-Juan,Zeng, Zheng-Zhi
experimental part, p. 503 - 511 (2011/03/21)
The binding properties on [PrL2(NO3)](NO 3)2 (L = 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1- piperaziny)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carbaldehyde benzoyl hydrazone) to bovine serum albumin (BSA
